Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02500199
Recruitment Status : Recruiting
First Posted : July 16, 2015
Last Update Posted : March 26, 2019
Sponsor:
Information provided by (Responsible Party):
Hengrui Therapeutics, Inc.

Brief Summary:

Part 1: to assess the safety and tolerability of pyrotinib and to define the maximum tolerated dose (MTD) of pyrotinib in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors (metastatic breast cancer, gastric cancer, or other solid tumors that have no targeted agent as standard of care).

Part 2: to estimate the overall response rate (ORR) for patients with HER2-positive metastatic breast cancer (mBC) and HER2 mutant non-small cell lung cancer (NSCLC) treated at the RP2D (or MTD).


Condition or disease Intervention/treatment Phase
Breast Cancer Gastric Cancer Solid Tumors NSCLC Drug: Pyrotinib Phase 1

Detailed Description:

This is an open-label, dose escalation study of repeated doses of pyrotinib in patients with HER2-positive advanced solid tumors, including breast cancer, non small cell lung cancer.

Part 1 of the trial is dose escalation and is designed to enroll 3 to 6 patients in each dose group. Adverse events (AEs) will be assessed and monitored throughout the study. Dose-limiting toxicities (DLT) will be assessed from the first dose of study drug through day 28 in the first cycle of treatment.

Part 2 of the trial will consist of two independent arms: arm A for HER2 positive mBC and arm B for NSCLC with documented HER2 mutation will be investigated to further evaluate safety and the preliminary effectiveness and clinical benefits of pyrotinib as a single agent.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy
Study Start Date : June 2015
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Pyrotinib
A two-part Phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
Drug: Pyrotinib
Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
Other Name: SHR1258




Primary Outcome Measures :
  1. Part 1 Maximum Tolerated Dose (MTD) [ Time Frame: Day 1 to 28 ( Cycle 1) ]
    to assess safety and tolerability of pyrotinib with a maximum tolerated dose (MTD) of pyrotinib in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors (metastatic breast cancer, gastric or other solid tumors with no targeted agent as standard of care).

  2. Part 2 Overall Response Rate (ORR) [ Time Frame: up to 24 months after the first dose ]
    to estimate the overall response rate (ORR) for patients with HER2-positive metastatic breast cancer (mBC) and HER2 mutant non-small cell lung cancer (NSCLC) treated at the RP2D (or MTD).


Secondary Outcome Measures :
  1. Maximum plasma concentration(Cmax) [ Time Frame: Up to 3 cycles(each cycle 28 days) ]
  2. Time to Cmax [ Time Frame: Up to 3 cycles(each cycle 28 days) ]
  3. Terminal half life (t1/2) [ Time Frame: Up to 3 cycles(each cycle 28 days) ]
  4. Area under the plasma concentration-time curve [ Time Frame: Up to 3 cycles(each cycle 28 days) ]
  5. Volume of distribution(V/F) [ Time Frame: Up to 3 cycles(each cycle 28 days) ]
  6. Plasma Clearance(CL/F) [ Time Frame: Up to 3 cycles(each cycle 28 days) ]
  7. Progression Free Survival (PFS) [ Time Frame: up to 24 months after the first dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

The study is open to all males and females who meet the following inclusion criteria at screening and baseline to participate in the study.

To be included to participate in this study each patient must:

  • be ≥ 18 years of age;
  • have an Eastern Cooperative Oncology Group performance status of 0-1 (not declining within past 2 weeks, see Appendix 1);
  • have confirmed HER2 gene amplified tumor fluorescence in-situ hybridization (FISH, HER2/cep17 ratio > 2) or HER2 overexpression (IHC 3+) or documented HER2 gene mutation. Documentation of HER2 status using FDA approved test(s) for HER2 testing specific for HER2 breast and gastric cancer is required prior to screening;
  • for part 1:

    1. Patients with HER2 positive (defined as documented overexpression or amplification or mutation) metastatic breast cancer who have experienced disease progression following at least 2 prior anti-HER2 therapies for metastatic disease that contain trastuzumab with or without pertuzumab, prior T-DM1, or lapatinib therapy is required;
    2. Patients with HER2 positive metastatic gastric cancer who have disease progression on prior trastuzumab therapy;
    3. other HER2-positive solid tumors (defined as documented overexpression or amplification or mutation) that have no approved targeted agent as standard of care
  • for part 2:

    1. Patients with HER2 positive metastatic breast cancer who have experienced disease progression after at least 2 prior anti-HER2 therapies for metastatic disease that contain trastuzumab with or without pertuzumab, prior T-DM1, or lapatinib therapy is required;
    2. Patients with documented HER2 mutated NSCLC whose disease progressed on prior therapy;
    3. Patients in Part 2 extension must have at least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria;
  • Left ventricular ejection fraction within institutional limits of normal (by multi gated acquisition scan or echocardiography;
  • have the required screening laboratory values including the following parameters:

    1. Absolute neutrophil count ≥ 1.5×109/L (1,500/mm3);
    2. Platelets ≥ 75×109/L (75,000/mm3);
    3. Hemoglobin ≥ 9.0 g/dL (90 g/L);
    4. Total bilirubin ≤ 1.5× upper limit of normal (ULN);
    5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN; for patients with liver metastases, ALT and AST ≤ 5×ULN;
    6. Serum creatinine ≤ 1.5×ULN;
  • have a life expectancy of > 12 weeks;
  • for female patients who are of child bearing potential, a negative serum pregnancy test result before study entry. A female patient of childbearing potential is one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or other means of birth control or whose sexual partners are either sterile or using contraceptives;
  • and who have provided informed consent by signing the informed consent form.

Main Exclusion Criteria:

Patients who meet any of the criteria listed below will not be eligible for participation in this study. A patient will not be eligible for study participation if:

  • is unable or unwilling to swallow pyrotinib;
  • has been < 2 weeks since the last radiotherapy, chemotherapy, hormone therapy, surgery or molecule-target therapy (< 6 weeks if chemotherapy included nitrosoureas or mitomycin);
  • the bone or skin is the only site of disease (for Part 2 extension only);
  • has pleural or peritoneal only disease;
  • has uncontrolled ≥ grade 2 hypokalemia and hypomagnesemia;
  • has had other cancer(s) within 5 years prior to screening with the exception of contralateral breast carcinoma, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin;
  • has active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with a history of CNS metastases or cord compression are allowable if they have been definitively treated and have been clinically stable for at least 4 weeks, and off steroids and anticonvulsants, before first dose of study drug);
  • has either QTcF prolongation (> 470 ms for female and > 450 ms for male), a known history of QTcF prolongation or Torsade de Pointes; or is on drugs that are required for existing medical conditions and that may result in QT prolongation (e.g., anti-arrhythmic drugs); patients who use medications that have a minimal impact on the QTcF interval in the Arizona-CERT criteria are allowed to participate in this study at Investigator's discretion based on his/her clinical assessment);
  • has a significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or ≥ grade 2 diarrhea of any etiology at baseline);
  • has participated in any other investigational drug clinical studies within the last 4 weeks;
  • is concurrently receiving other anti-tumor therapies at time of study screening visit;
  • has an active infection (per Investigator judgment);
  • has a history of immunodeficiency including seropositive for human immunodeficiency virus, or has other acquired or congenital immunodeficient disease;
  • has evidence of uncontrolled heart disease, including (1) congestive heart failure (New York Heart Association functional classification) of ≥ 2), (2) angina requiring treatment (3) myocardial infarction within the past 12 months, or (4) any clinically significant supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention;
  • has allergies or a known history of hypersensitivity to any components of the pyrotinib;
  • is female and of childbearing potential (WOCBP) who is unwilling or unable to use an acceptable method (barrier methods only) to avoid pregnancy for the entire study period and for up to 28 days post last dose;
  • is female and pregnant (or found to be pregnant at screening) or breastfeeding;
  • evidence of significant medical illness or an abnormal laboratory finding, which according to the Investigator's judgment, will substantially increase the risk of participation in and completion of the study. Including, but not limited to, serious ongoing infection (ie, requiring intravenous antibiotic or antiviral agent), uncontrolled major seizure disorder, or significant pulmonary disorder (e.g. interstitial pneumonitis, pulmonary hypertension); hypertension (> grade 3), severe diabetes (uncontrolled > grade 3 hyperglycemia), serious ongoing infection or thyroid disease;
  • has a known history of neurological psychiatric disease including epilepsy or dementia that would interfere with patient's ability to participate in the study or to provide consent;
  • has had prior exposure to any other investigational HER2 targeted agents within 4 weeks of screening visit.
  • is currently taking strong CYP3A4 inhibitor or concomitant meds.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02500199


Contacts
Layout table for location contacts
Contact: Junsheng Wang, MD (609)423-2155 ext 205 junsheng.wang@hengruitx.com
Contact: Greg Berk, MD 508-785-1063 greg.berk@hengruitx.com

Locations
Layout table for location information
United States, California
University of California, Irvine School of Medicine Recruiting
Orange, California, United States, 92868
Contact: Viola Zhu, MD    714-456-8105    zhuvw@uci.edu   
Principal Investigator: Viola Zhu, MD         
UC Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Tianhong Li, MD    916-734-3772    thli@ucdavis.edu   
Principal Investigator: Tianhong Li, MD         
United States, Florida
Florida Cancer Specialists Recruiting
Sarasota, Florida, United States, 34232
Contact: Manish Patel, MD    941-377-9993    mpatel@flcancer.com   
Principal Investigator: Manish Patel, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Alice Shaw, MD,Ph.D    617-724-4000    ashaw1@partners.org   
Principal Investigator: Alice Shaw, MD         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Brian Beardslee    617-632-5638    brian_beardslee@dfci.harvard.edu   
Principal Investigator: Geoffrey Shapiro, MD         
United States, Michigan
Henry Ford Health System Recruiting
Detroit, Michigan, United States, 48202
Contact: Ding Wang    313-916-3721    dwang1@hfhs.org   
Principal Investigator: Ding Wang, MD         
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Cindy Fogal    314-362-1518    cfogal@wustl.edu   
Principal Investigator: Saiama Waqar, MD         
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Ann Elizabeth Sisk    646-888-4396      
Principal Investigator: Bob Li, MD         
United States, Tennessee
Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
Contact: Melisa Johnson, MD       mjohnson@tnonc.com   
Principal Investigator: Melissa Johnson, MD         
United States, Texas
South Texas Accelerated Research Therapeutics Completed
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Hengrui Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Junsheng Wang, MD Hengrui Therapeutics, Inc.

Layout table for additonal information
Responsible Party: Hengrui Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02500199     History of Changes
Other Study ID Numbers: SHRUS 1001
First Posted: July 16, 2015    Key Record Dates
Last Update Posted: March 26, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Hengrui Therapeutics, Inc.:
HER2 positive
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases